Results 111 to 120 of about 25,638 (254)

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

open access: yesAndrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli   +7 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

open access: yes, 2019
Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-
Wright AM, Clements JN, Howell R
core  

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

open access: yes, 2010
Mahamood Edavalath1, Jeffrey W Stephens1,21Department of Diabetes and Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, UK; 2Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea, UKAbstract: Type 2 diabetes
Jeffrey W Stephens, Mahamood Edavalath
core  

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression

open access: yes, 2015
Yimin Shao, Geheng Yuan, Junqing Zhang, Xiaohui Guo Department of Endocrinology, Peking University First Hospital, Beijing, People’s Republic of China Abstract: Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight ...
Shao Y, Zhang J, Guo X, Yuan G
core  

Acute Pancreatitis Associated with Liraglutide

open access: yes, 2011
Objective: To report what is, to our knowledge, the first postmarketing case of acute pancreatitis associated with liraglutide Case Summary: A 60-year-old female with type 2 diabetes presented with a 16-hour history of mid-epigastric pain 3 weeks after ...
M David Stockton   +2 more
core   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy